Characterization of two cyclic metabolites of sitagliptin

Drug Metabolism and Disposition

Volumn 35, Issue 4, 2007, Pages 521-524

  Liu, David Q ^a   Arison, Byron H ^a   Stearns, Ralph A ^a   Kim, Dooseop ^a   Vincent, Stella H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE; DRUG METABOLITE; PIPERAZINE; SITAGLIPTIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYCLIZATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD26; BIOTRANSFORMATION; CYCLIZATION; DOGS; ENZYME INHIBITORS; HYPOGLYCEMIC AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PYRAZINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; TRIAZOLES;

CANIS FAMILIARIS;

EID: 34047112815     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013128     Document Type: Article

References (11)

1. Beconi MG, Reed JR, Teffera Y, Xia Y-Q, Kochansky CJ, Liu, DQ, Xu S, Elmore CS, Ciccotto S, Hora DF, et al. (2007) Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. 35:000-000.
2. Bergman A, Krishna R, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, et al. (2005) Lack of a pharmacokinetic food effect and evaluation of the definitive bioavailability of sitagliptin (MK-0431), an oral dipeptidyl peptidase-IV inhibitor. J Clin Pharm 45:1089.
3. Bergman AJ, Stevens C, Zhou YY, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, et al. (2006) Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebocontrolled study in healthy male volunteers. Clin Ther 28:55-72.
4. Herman G, Hanefeld M, Wu M, Chen X, Zhao P, and Stein P (2005a) Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetes 54 (Suppl 1):A134.
5. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, et al. (2005b) Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharmacol Ther 78:675-688.
6. Herman GA, Zhao PL, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Hilliard D, Tanen M, et al. (2004) The DP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetics. Diabetes 53 (Suppl 2):A82.
7. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey G-J, Kowalchick JE, Leiting B, Lyons K, et al. (2005) (2R)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4, 5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141-151.
8. Leiting B, Pryor KD, Wu JK, Marsilio F, Patel RA, Craik CS, Ellman JA, Cummings RT, and Thornberry NA (2003) Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J 371:525-532.
9. Liu DQ, Hop CE, Beconi MG, Mao A, and Chiu SH (2001) Use of on-line hydrogen/deuterium exchange to facilitate metabolite identification. Rapid Commun Mass Spectrom 15:1832-1839.
10. Scott R, Herman G, Zhao P, Chen X, Wu M, and Stein P (2005). Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes (T2D). Diabetes 54 (Suppl 1):A10.
11. 14C]sitagliptin in humans. Drug Metab Dispos 35:000-000.